Home / Business and Economy / Alcohol Sales Dip as GLP-1 Drugs Pose New Challenge
Alcohol Sales Dip as GLP-1 Drugs Pose New Challenge
10 Sep
Summary
- US alcoholic beverage consumption is at historic lows.
- GLP-1 drug users also consume alcohol, but intake is inconclusive.
- Boston Beer and Molson Coors see declining volumes and stock prices.
US alcoholic beverage consumption is currently at historic lows, a trend impacting major brewers. Heineken's US CEO, Maggie Timoney, addressed the phenomenon, noting that individuals using GLP-1 weight-loss drugs also consume alcohol, though the extent of this consumption is still being studied. This comes as companies like Brown-Forman, Molson Coors, and Boston Beer report declining sales.
Boston Beer's Q2 FY2026 results showed a significant miss on adjusted EPS and a 3.3% decrease in revenue year-over-year, with depletions falling 6%. The company increased advertising spend to defend market share. Founder Jim Koch acknowledged pressure on all alcoholic beverages, citing a slight offset from premiumization and updated health guidelines.
Molson Coors also experienced a 3.3% drop in net sales and a 5.4% decrease in financial volume during Q2. CEO Rahul Goyal is steering the company towards a 'beyond beer' strategy, including partnerships and acquisitions, to counter volatility in the traditional beer market.
Looking ahead, consumer sentiment remains low, creating a challenging environment for discretionary spending. While Heineken 0.0 has seen substantial growth, its long-term market share is projected to be modest. Investors are watching to see if US industry volumes can stabilize and if 'beyond beer' investments can offset declines in core brands, especially with the ongoing debate around GLP-1 drugs.
